§ Ms. Richardsonasked the Secretary of State for Social Services (1) whether he intends to publish details of the kind of post-marketing surveillance which will be undertaken on Depo Provera;
(2) whether the manufacturers will be required to provide the leaflet on Depo Provera which doctors give to women in all languages spoken in Britain, particularly Asian languages;
(3) when the new product data sheet on Depo Provera will be completed.
§ Mr. Kenneth ClarkeA revised data sheet will be published when the product licence for long-term contraceptive use of Depo Provera is issued. We are now waiting for the manufacturer of Depo Provera to put proposals to us about post-marketing surveillance as soon as the necessary arrangement have been made. We are still consulting the manufacturers about which languages, other than English, the patient leaflet should be printed.
§ Ms. Richardsonasked the Secretary of State for Social Services how many injections of Depo Provera are used per year by National Health Service maternity units of hospitals with rubella vaccinations in the immediate post-partum period.
§ Mr. Kenneth ClarkeWe do not collect information centrally on injections carried out in those circumstances.